Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Catherine Ju-Ying Wu, M.D.

Co-Author

This page shows the publications co-authored by Catherine Wu and Edward Fritsch.
Connection Strength

3.470
  1. Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved. Cancer Immunol Res. 2020 12; 8(12):1465-1469.
    View in: PubMed
    Score: 0.947
  2. Personal neoantigen cancer vaccines: The momentum builds. Oncoimmunology. 2014; 3:e29311.
    View in: PubMed
    Score: 0.606
  3. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res. 2014 Jun; 2(6):522-9.
    View in: PubMed
    Score: 0.593
  4. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature. 2021 08; 596(7870):119-125.
    View in: PubMed
    Score: 0.247
  5. A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood. 2018 11 01; 132(18):1911-1921.
    View in: PubMed
    Score: 0.202
  6. Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2018 03 14; 555(7696):402.
    View in: PubMed
    Score: 0.196
  7. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 07 13; 547(7662):217-221.
    View in: PubMed
    Score: 0.187
  8. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014 Jul 17; 124(3):453-62.
    View in: PubMed
    Score: 0.151
  9. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res. 2013 Jul; 1(1):11-5.
    View in: PubMed
    Score: 0.139
  10. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021 03; 27(3):515-525.
    View in: PubMed
    Score: 0.060
  11. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239.
    View in: PubMed
    Score: 0.052
  12. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol Immunother. 2019 Mar; 68(3):421-432.
    View in: PubMed
    Score: 0.052
  13. Vaccines and melanoma. Hematol Oncol Clin North Am. 2014 Jun; 28(3):559-69.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.